New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 7, 2014
07:19 EDTRDS.A, BP, STOBP says potential oil-price manipulation probed by U.S., EU, Asian regulators
BP (BP), in its annual report filed yesterday, disclosed that in May 2013, European Commission officials made a series of unannounced inspections at the offices of BP and other companies involved in the oil industry acting on concerns that anticompetitive practices may have occurred in connection with oil price reporting practices and the reference price assessment process. "Such inspections are a preliminary step in investigations. There is no deadline for the completion of the inquiries," BP said. BP added that related inquiries and requests for information have also been received from U.S. and other regulators following the European Commissionís actions. In June 2013, the Federal Trade Commission served BP with a Request for Voluntary Submission of Documents and Information regarding its non-public investigation into whether or not Shell (RDS.A), BP or Statoil (STO) have engaged in unfair methods of competition or manipulative or deceptive conduct. BP said it is producing documents to the FTC. Also in June 2013, BP received an initial request for information from the Japanese Fair Trade Commission and in December 2013, the Korea Fair Trade Commission initiated an investigation and a first information request is expected to be issued. In January 2014, the U.S. Commodity Futures Trading Commission requested price reporting documents from BP, the company added.
News For A;STO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 6, 2015
07:23 EDTAAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
October 5, 2015
05:29 EDTADako announces FDA approval of new companion diagnostic assay
Subscribe for More Information
October 2, 2015
15:57 EDTALabCorp to offer PD-L1 companion diagnostic
Subscribe for More Information
15:43 EDTAQuest Diagnostics introduces Dako's PD-L1 companion diagnostic for KEYTRUDA
Subscribe for More Information
15:25 EDTAAgilent's Dako confirms FDA approval of NSCLC diagnostic
Dako, an Agilent Technologies (A) company and a worldwide provider of cancer diagnostics, announced the FDA approval of a new companion diagnostic assay that can reveal whether a patient with advanced non-small cell lung cancer, or NSCLC, is likely to respond to a new form of treatment. The approval of PD-L1 IHC 22C3 pharmDx strengthens Dako's portfolio of companion diagnostics and the company's leadership position in developing and commercializing companion diagnostic products. Dako developed PD-L1 IHC 22C3 pharmDx in partnership with Merck (MRK), maker of the anti-PD-1 therapy Keytruda. The FDA approved PD-L1 IHC 22C3 pharmDx for use in the United States. Dako hopes to gain regulatory approval for the new diagnostic in Canada, Europe and other jurisdictions next year.
September 24, 2015
17:04 EDTAMerck, Pfizer to collaborate with Agilent's Dako on Avelumab diagnostic
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use